Seven Finnegan Attorneys Named to the 2025 IAM Strategy 300 List

FOR IMMEDIATE RELEASE
August 13, 2025

WASHINGTON, DC—Intellectual Asset Management (“IAM”) released its annual guide, IAM Strategy 300: The World’s Leading IP Strategist, naming seven Finnegan attorneys to the 2025 list. IAM Strategy 300 identifies the top practitioners from around the world who are elevating IP portfolio management and leading the way in developing and executing strategies that maximize the value of IP portfolios. To be included in the IAM Strategy 300, all individuals must be nominated by at least three individuals outside of their organization. The selection process also includes comprehensive research involving in-person meetings, telephone interviews, and conversations with senior figures from the global IP community. Finnegan is proud of the seven attorneys recognized in 2025 IAM Strategy 300. Learn more about them below:

Dr. Antje Brambrink is qualified and admitted as a German attorney at law and as a representative before the Unified Patent Court (UPC). She advises and represents clients in complex, often cross-border patent disputes, frequently at the interface of antitrust and regulatory laws. Antje is experienced in infringement, preliminary injunction, inspection, nullity and compulsory license proceedings as well as the coordination of cross-border patent disputes. Her expertise covers a broad range of technologies. Based on her dual qualification as a dentist she has a deep understanding of the life sciences sector, including pharmaceuticals, biotechnology, chemicals, and medical devices. In addition to her work as a litigator, Antje advises clients strategically on all IP-related matters in the context of patent litigation such as licensing or the transfer of rights.

Justin Hasford focuses on complex patent litigation at the trial and appellate levels on behalf of pioneer pharmaceutical companies. He has particular experience with cases arising from Abbreviated New Drug Applications under the Hatch-Waxman Act. Justin counsels clients on issues of infringement, validity, enforceability, antitrust, unfair competition, licensing, due diligence, and IP portfolio management. He has extensive experience advising clients regarding the interplay between patent and regulatory laws, including Orange Book listing of patents for drugs approved by the Food and Drug Administration. Justin has also litigated antitrust cases and business method patent cases.

Christopher Johns maintains a diverse patent practice, ranging from patent application drafting, international patent prosecution, and strategic portfolio development to district court litigation, International Trade Commission investigations, Patent Trial and Appeal Board (PTAB) trials, and appeals to the U.S. Court of Appeals for the Federal Circuit. On the prosecution and client counseling side, Chris has experience drafting, prosecuting, and appealing patent applications related to electronics, software, telecommunications, shipping and logistics, and business methods. He provides domestic and international clients with strategic IP counseling, including portfolio management and drafting strategies. Chris has a particular focus on patent eligibility under 35 U.S.C. § 101 and has extensive experience with inter partes review (IPR) and covered business method proceedings before the PTAB, district court litigations, and ITC investigations.

Karthik Kumar, Ph.D. focuses on competitor patent and trade secrets litigation, and strategic counseling related to emerging technologies. As part of his strategic counseling work, Karthik manages the global patent portfolios of several world-renowned technology companies focusing on 5G, artificial intelligence and machine learning, blockchain, and Internet-of-Things. He also serves as co-lead of Finnegan’s augmented reality/virtual reality industry working group.

Leslie McDonell provides strategic counseling to both startups and larger companies on the procurement and protection of intellectual property in the pharmaceutical and biotechnology industries. She has extensive experience in conducting due diligence investigations and preparing companies to be the target of due diligence, pre-litigation analyses, and offensive and defensive post-grant proceedings. Leslie has represented clients before the U.S. Patent and Trademark Office in patent appeals, interferences, reissues, reexaminations, and IPRs. Her U.S. litigation experience includes representation of both plaintiffs and defendants in biotechnology and pharmaceutical cases. She coordinates worldwide patent portfolio strategies; evaluates and analyzes competitors’ patent positions around the world; and advises and renders opinions on issues of patentability, inventorship, validity, claim scope, infringement, and freedom-to-operate.

Maeve O'Flynn is a European and UK patent attorney with more than a decade of in-house experience, having worked at some of the world’s largest multinational corporations in the oil and chemical industries. She has worked for a range of clients, from startups to multinationals, covering diverse technologies such as cosmetics, sustainable chemistry, and catalysis. Maeve helps clients develop commercially relevant intellectual property strategies. This includes developing and managing global patent portfolios, provisioning advice regarding trade secrets and defensive publications, and negotiating collaboration and licensing agreements. Maeve has extensive experience preparing and prosecuting patent applications, from the initial invention harvesting sessions through to achieving allowance. She works with clients to assess and value their patent portfolios, and to develop filing strategies that support their commercial aims. She also represents clients at oral proceedings before the EPO, representing both patentee and opponent.

Anthony Tridico, Ph.D., former managing partner of Finnegan’s London office, has worked in Europe for most of his career, gaining significant knowledge of the European Patent Convention and the diversity of laws and practice among the European national systems. His knowledge of the various legal systems and how they differ from the U.S. allows Anthony to effectively counsel clients across life sciences industries with global interests in intellectual property. Anthony has over 20 years of experience representing clients with a focus on patent office trials and appeals before the PTAB and the EPO, patent prosecution management, IP due diligence, and litigation. His practice includes experience in a variety of technical areas, including biologics, immunology and biotechnology, chemical and pharmaceutical sciences, polymers and adhesives, food sciences, medical devices, and diagnostics and instrumentation.

Contacts

Terra Liddell, Chief Marketing Officer
terra.liddell@finnegan.com

Angela Robinson, Director of Branding and Communications
angela.robinson@finnegan.com

About Finnegan
When your most valuable assets are ideas, innovation, and brand—you need the best to protect them. Finnegan, a premier intellectual property law firm, is trusted by global leaders to protect and advance what sets them apart. With 11 offices across the globe, we bring local insight and global reach to every IP challenge. We are located in Atlanta, Boston, London, Munich, Palo Alto, Reston, Seoul, Shanghai, Taipei, Tokyo and Washington, DC. From high-stakes litigation to cutting-edge patent strategy and innovative brand management, we deliver unmatched depth, agility, and results. If it is IP, it is Finnegan. Please visit us at www.finnegan.com or follow us on LinkedIn to see how we’re shaping the future of IP, one breakthrough at a time.